secwatch.observer — SEC 8-K summary
======================================

Issuer:     EKSO BIONICS HOLDINGS, INC. (CHRN)
CIK:        0001549084
Form:       8-K
Filed at:   2024-07-29T23:59:59+00:00
Accession:  0001437749-24-023753
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ekso Bionics reports record Q2 sales of $5.0M; net loss narrows to $0.13 per share
--------------------------------------------------------------------------------

- Revenue $5.0M up 5% YoY; gross margin improved to 53% from 48%.
- Net loss $2.4M ($0.13/sh) vs $4.2M ($0.31/sh) in Q2 2023, narrowing significantly.
- Sold 37 EksoHealth devices in Q2; initial Medicare claims for Ekso Indego Personal pending.
- Operating expenses decreased across all categories: SG&A down 21%, R&D down 20%, G&A down 28%.
- Cash at June 30, 2024 $5.9M, down from $8.6M at Dec 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549084/000143774924023753/0001437749-24-023753-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549084/000143774924023753/ekso20240726c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-023753

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer